VANCOUVER, British Columbia--(BUSINESS WIRE)--

ProtoKinetix (PKTX) (www.protokinetix.com) announces the formation of a new structure that allows the Company the flexibility of financing through a subsidiary, partnering through a subsidiary or selling the subsidiary. These new entities will contain rights to clearly defined AAGP applications that can easily be segregated from the overall asset base.

Due to recent discussions and testing, the first subsidiary to be formed will be for the large (estimated to be $40 to $50-Billion annually worldwide and growing) monoclonal antibody production market. Those rights will have significant value in increasing the productivity of hybridoma cells which make monoclonal antibodies. In one test AAGP increased the production of antibodies by 300% and in another test by 500%.

AAGP bio assays (which can be viewed at our revised web site) show that AAGP has an important role in Regenerative Medicine. Regenerative Medicine is the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function and is becoming one of the largest growth industries in healthcare.

ProtoKinetix anticipates the requirement to establish several subsidiaries to maximize the financial returns for its shareholders.

About ProtoKinetix

ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP) for medicine and the biotechnology and cosmetic industries. PKTXs primary focus is on the therapeutic potential for AAGP in the treatment of Diabetes, inflammatory diseases, skin protection and anti-aging.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Companys filings with the Securities and Exchange Commission.

Ross L. Senior President and CEO

Read the original here:
ProtoKinetix Creates Subsidiaries for AAGP™ Applications to Maximize Shareholder Value